Needham & Company Perplexed by Oncolytics (ONCY) H&N Trial Data Release But 'Staying the Course'
Tweet Send to a Friend
Needham & Company analyst Chad Messer, Ph.D. said he's staying the course on Oncolytics Biotech (NASDAQ: ONCY) amid controversial reolysin ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
